Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;31(4):837-48.
doi: 10.1007/s11011-016-9809-y. Epub 2016 Mar 5.

Piperine Potentiates the Effects of Trans-Resveratrol on Stress-Induced Depressive-Like Behavior: Involvement of Monoaminergic System and cAMP-dependent Pathway

Affiliations

Piperine Potentiates the Effects of Trans-Resveratrol on Stress-Induced Depressive-Like Behavior: Involvement of Monoaminergic System and cAMP-dependent Pathway

Ying Xu et al. Metab Brain Dis. .

Abstract

Stress can act as a precipitation factor in the onset of emotional disorders, particularly depression. Trans-resveratrol is a polyphenolic compound enriched in polygonum cuspidatum and has been found to exert antidepressant-like effects in our previous studies. In present study, we assessed the effects of trans-resveratrol used in combination with piperine, commonly known as a bioavailability enhancer, on chronic unpredictable mild stress-induced depressive-like behaviors and relevant molecular targets. Trans-resveratrol used alone reduced the immobility time of rats in the forced swimming test, with the maximal effects of trans-resveratrol around 60 % inhibition at the highest dose tested, 40 mg/kg. However, when a subthreshold dose of piperine, 2.5 mg/kg was used in combination with trans-resveratrol, the minimum effective dose of trans-resveratrol in reducing the immobility time was reduced to 20 mg/kg. Further evidence from neurochemical (monoamines in the frontal cortex and the hippocampus), biochemical (monoamine oxidase, MAO activities) and molecular biological (cAMP, PKA, CREB and BDNF) assays supported the findings in the behavioral studies. These results suggest that the co-treatment strategy with trans-resveratrol and piperine might be an alternative therapy that provides efficacious protection against chronic stress.

Keywords: Depression; Forced swimming; Monoamine; Piperine; Trans-resveratrol; cAMP signaling.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Metab Brain Dis. 2013 Dec;28(4):585-95 - PubMed
    1. Psychosom Med. 2008 May;70(4):435-43 - PubMed
    1. Pharmacol Biochem Behav. 2005 Sep;82(1):200-6 - PubMed
    1. Biol Psychiatry. 2005 Dec 15;58(12):955-62 - PubMed
    1. Br J Psychiatry. 1984 Feb;144:161-6 - PubMed

MeSH terms

LinkOut - more resources

Feedback